Sugi Predict

Sugi Predict / Compounds / SCHEMBL8083539

SCHEMBL8083539

SCHEMBL8083539

N[C@H](Cc1cccc([N+](=O)[O-])c1)C(=O)O

nearest known ligand 0.63

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ GRM8 O00222 2/20 0.63
▸ GRM4 Q14833 2/20 0.63
▸ GRM6 O15303 1/20 0.63
▸ KMO O15229 1/20 0.62
▸ SLC7A5 Q01650 3/20 0.57
▸ ALPI P09923 1/20 0.57
▸ PKM P14618 1/20 0.57
▸ PTGS1 P23219 1/20 0.57
▸ XIAP P98170 1/20 0.57
▸ GRIA2 P42262 1/20 0.55
▸ NOS3 P29474 2/20 0.54
▸ NOS1 P29475 2/20 0.54
▸ NOS2 P35228 2/20 0.54
▸ TSHR P16473 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL44005 1.00 GRM8 (0.63) GRM8GRM4GRM6KMOSLC7A5
SCHEMBL29616010 1.00 GRM8 (0.63) GRM8GRM4GRM6KMOSLC7A5
SCHEMBL30232038 1.00 GRM8 (0.63) GRM8GRM4GRM6KMOSLC7A5
SCHEMBL44004 1.00 GRM8 (0.63) GRM8GRM4GRM6KMOSLC7A5
Hydrochloric Acid SCHEMBL8127068 0.98 GRM8 (0.62) GRM8GRM4GRM6KMOSLC7A5
Hydrochloric Acid SCHEMBL6747798 0.98 GRM8 (0.62) GRM8GRM4GRM6KMOSLC7A5
Hydrochloric Acid SCHEMBL6747799 0.98 GRM8 (0.62) GRM8GRM4GRM6KMOSLC7A5
Dl-Phenylalanine SCHEMBL27765394 0.93 ALPI (0.65) GRM8GRM4GRM6KMOSLC7A5
SCHEMBL13660573 0.86 SLC7A5 (0.59) GRM8GRM4GRM6SLC7A5ALPI
Tyrosine SCHEMBL27411908 0.86 SLC7A5 (0.65) GRM8GRM4GRM6KMOSLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160022636-A1 PHYSIOLOGICAL LIGANDS FOR GPR139 JANSSEN PHARMACEUTICA NV (BE) 2016-01-28 — — US claimed
EP-2968240-A2 PHYSIOLOGICAL LIGANDS FOR GPR139 Janssen Pharmaceutica, N.V. (BE) 2016-01-20 — — EP claimed
US-20140336216-A1 PHYSIOLOGICAL LIGANDS FOR GPR139 JANSSEN PHARMACEUTICA NV (BE) 2014-11-13 — — US claimed
WO-2014152917-A2 PHYSIOLOGICAL LIGANDS FOR GPR139 JANSSEN PHARMACEUTICA NV (BE) 2014-09-25 — — WO claimed
US-20260083834-A1 CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY TRANSFERT PLUS LP (CA) 2026-03-26 — — US disclosed
US-20250367300-A1 Nanomaterial and Methods of Use Thereof UNIVERSITY OF CONNECTICUT (US) 2025-12-04 — — US disclosed
US-20250302762-A1 NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF UNIVERSITY OF CONNECTICUT (US) 2025-10-02 — — US disclosed
US-20250302971-A1 Therapeutic Nanomaterials UNIV CONNECTICUT (US) 2025-10-02 — — US disclosed
US-20250229081-A1 NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF UNIVERSITY OF CONNECTICUT 2025-07-17 — — US disclosed
EP-4584301-A1 CSGA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY Transfert Plus, Limited Partnership (CA) 2025-07-16 — — EP disclosed
EP-4578867-A1 CYCLIC PEPTIDE OR SALT THEREOF AND MDMX INHIBITOR FUJIFILM Corporation (JP) 2025-07-02 — — EP disclosed
EP-4578868-A1 CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR FUJIFILM Corporation (JP) 2025-07-02 — — EP disclosed
US-20130210745-A1 TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. (US) 2013-08-15 — — US disclosed
US-20130123169-A1 PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. (US) 2013-05-16 — — US disclosed
CN-1202096-C 2-aminothiazoline derivatives and their use as no-synthase inhibitors AVENTIS PHARMA SA (FR) 2005-05-18 — — CN disclosed
CN-1444572-A 2-aminothiazoline derivatives and their use as no-synthase inhibitors AVENTIS PHARMA SA (FR) 2003-09-24 — — CN disclosed
EP-0555537-B1 Endothelin antagonists BANYU PHARMA CO LTD (JP) 2000-11-02 — — EP disclosed
US-5614498-A OLIGOPEPTIDES, BRONCHDILATORS BANYU PHARMACEUTICAL CO., LTD. (JP) 1997-03-25 — — US disclosed
US-5496928-A Endothelin antagonistic substance BANYU PHARMACEUTICAL CO., LTD. (JP) 1996-03-05 — — US disclosed
EP-0555537-A2 Endothelin antagonistic substance BANYU PHARMACEUTICAL CO., LTD. (JP) 1993-08-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250302971-A1 Therapeutic Nanomaterials TIE1, TEKT1, POLRMT GRM8 3193/4885GRM4 3889/4885GRM6 3328/4885
US-20250367300-A1 Nanomaterial and Methods of Use Thereof EPCAM, CD47, JAK2 GRM8 3118/4885GRM4 2609/4885GRM6 1893/4885
US-20250302762-A1 NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF JAK2, JAK1, CHMP4B GRM8 2510/4885GRM4 2568/4885GRM6 2593/4885
US-20260083834-A1 CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY VSIG8, MICA, CD74 GRM8 731/4885GRM4 1398/4885GRM6 1010/4885
US-20130123169-A1 PEPTIDOMIMETIC MACROCYCLES GHRHR, GHSR, GHITM GRM8 1308/4885GRM4 614/4885GRM6 1132/4885
US-20130210745-A1 TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES IL33, TPR, CDC37 GRM8 1681/4885GRM4 1904/4885GRM6 3751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.